Effect of Prubucol and Simvastatin combination on hs-CRP and serum lipid level in patients with acute coronary syndrome

[Objective] To investigate the effects of Probucol combined with Simvastatin and Simvastatin only on serum lipid and high-sensitivity C-reactive protein (hs-CRP) levels after 1 month. [Methods] 79 ACS patients were assigned to Simvastatin only group (20 mg/d of simvastatin, n =39) or combined therapeutic group (20 mg/d of Simvastatin and 1.0 g/d of Probucol, n =40) in a randomized study. The levels of serum lipid and hs-CRP were detected before and after treatment. [Results] The levels of serum lipid and hs-CRP were significantly decreased in Simvastatin only group and combined therapeutic group (P 0.01), and those in combined therapy decreased even more markedly (P 0.05). [Conclusions] Both Simvastatin alone and Simvastatin combined Probucol can decrease the levels of serum lipid and hs-CRP in patients with ACS, which may reduce inflammatory reaction and stabilize plaque. Simvastatin combined with Probucol may have stronger effect on stabilizing plaque than Simvastatin alone.